iBio, Inc. is a clinical-stage biotechnology company specializing in plant-based expression systems to develop and manufacture therapeutic proteins and vaccines. The company’s proprietary FastPharming™ technology harnesses a transient expression platform in plant cells, enabling rapid production of recombinant biologics. This approach is designed to offer an alternative to traditional mammalian or microbial cell culture systems, with potential benefits in speed, scalability and cost-effectiveness.
Through its iBio CDMO division, iBio provides contract development and manufacturing services to pharmaceutical and biotechnology clients. Offerings include process development, analytical method development, and cGMP manufacturing of clinical- and commercial-scale biologics. The company’s integrated service model is intended to support candidates from early-stage development through commercial launch, encompassing activities such as gene construct optimization, upstream and downstream processing, and quality control testing.
Founded in 2000 as IBIO, Inc., the company has evolved its business by acquiring Greenovation Biotech GmbH in 2016, expanding its capabilities in Europe. In 2020, iBio opened its cGMP-compliant biomanufacturing facility in Bryan, Texas, near Texas A&M University, marking a significant milestone in its capacity to produce clinical-grade materials. The company’s headquarters are located in New York, reflecting its origins and ongoing strategic focus on U.S. innovation hubs.
iBio serves a global client base, with operations and collaborations spanning the United States and Europe. By leveraging its plant-based system, the company aims to address the growing demand for flexible biomanufacturing solutions and to accelerate the development of vaccines and therapeutic proteins for emerging health threats and chronic diseases.
AI Generated. May Contain Errors.
